2017_SBRT_Course Book

Individual Patient Data Meta-Analysis: NSCLC 757 NSCLC patients with 1-5 synchronous or metachronous mets

Median OS 26 months , 1-year OS 70.2%, and 5-year OS 29.4%

Surgery was the commonest treatment modality for both the primary (n=635, 83.9% ) and for metastases (n=339, 62.3% )

Recursive Partitioning Analysis for risk groups; Low-risk : metachronous metastase (5-year OS 48%)

Intermediate risk : synchronous metastases, N0 disease (5-year OS 36%)

High-risk : synchronous metastases, N1/N2 disease (5-year OS 14%)

Ashworth A, Clin Lung Cancer 2014